Search research articles
Contact Us
Filters
Showing results (71-80 of 116) with videos related to
Page
of 12
Sort By:
Melanoma Research
|
September 14, 2000
Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells
A J Schrader, M Probst-Kepper, J Grosse, et al.
Molecular Biotherapy
|
December 1, 1992
Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha
S Duensing, M Hadam, A Körfer, et al.
Oncology
|
March 1, 1996
Platelet endothelial cell adhesion molecule-1 (PECAM-1): a potential prognostic marker involved in leukocyte infiltration of renal cell carcinoma
G Anastassiou, S Duensing, G Steinhoff, et al.
World Journal of Urology
|
January 1, 1995
Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid
J Atzpodien, H Kirchner, S Duensing, et al.
American Journal of Clinical Oncology
|
June 1, 1994
Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy
A Schomburg, H Kirchner, E Lopez-Hänninen, et al.
The Clinical Investigator
|
July 1, 1994
Cytokine-based biotherapy of gastrointestinal tumors
J Buer, H Kirchner, A Schomburg, et al.
Cancer Research
|
December 1, 1991
Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes
E L Hänninen, A Körfer, M Hadam, et al.
Cancer Biotherapy
|
January 1, 1993
Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study
J Atzpodien, H Kirchner, P de Mulder, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
October 1, 1996
Linomide and interleukin-2 in patients with advanced renal cell carcinoma
M Deckert, A Franzke, J Buer, et al.
British Journal of Cancer
|
July 14, 1998
Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma
A Franzke, M Probst-Kepper, J Buer, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 116) with videos related to
Sort By:
Page
of 12
Melanoma Research
|
September 14, 2000
Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells
A J Schrader, M Probst-Kepper, J Grosse, et al.
Molecular Biotherapy
|
December 1, 1992
Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha
S Duensing, M Hadam, A Körfer, et al.
Oncology
|
March 1, 1996
Platelet endothelial cell adhesion molecule-1 (PECAM-1): a potential prognostic marker involved in leukocyte infiltration of renal cell carcinoma
G Anastassiou, S Duensing, G Steinhoff, et al.
World Journal of Urology
|
January 1, 1995
Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid
J Atzpodien, H Kirchner, S Duensing, et al.
American Journal of Clinical Oncology
|
June 1, 1994
Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy
A Schomburg, H Kirchner, E Lopez-Hänninen, et al.
The Clinical Investigator
|
July 1, 1994
Cytokine-based biotherapy of gastrointestinal tumors
J Buer, H Kirchner, A Schomburg, et al.
Cancer Research
|
December 1, 1991
Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes
E L Hänninen, A Körfer, M Hadam, et al.
Cancer Biotherapy
|
January 1, 1993
Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study
J Atzpodien, H Kirchner, P de Mulder, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
October 1, 1996
Linomide and interleukin-2 in patients with advanced renal cell carcinoma
M Deckert, A Franzke, J Buer, et al.
British Journal of Cancer
|
July 14, 1998
Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma
A Franzke, M Probst-Kepper, J Buer, et al.
Page
of 12